CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that Dr. Matt Coffey, Chief
Scientific Officer of Oncolytics, is scheduled to deliver a presentation on
Wednesday, December 5, 2007 entitled "Large Scale Production Process for
the Oncolytic Agent REOLYSIN(R) (Human Reovirus)" at the Informa Life
Sciences' 3rd Annual Vaccine Production Conference in Cologne, Germany. The
conference runs from December 4-5, 2007.
For more information about the conference, please visit
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com
This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's expectations related to
the manufacturing process presented at this conference, and the Company's
belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve
known and unknown risks and uncertainties, which could cause the Company's
actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success
and timely completion of clinical studies and trials, the Company's abilit
|SOURCE Oncolytics Biotech Inc.|
Copyright©2007 PR Newswire.
All rights reserved